Literature DB >> 12356677

The in vivo development of human T cells from CD34(+) cells in the murine thymic environment.

Yuki Saito1, Yoshie Kametani, Katsuto Hozumi, Naoko Mochida, Kiyoshi Ando, Mamoru Ito, Tatsuji Nomura, Yutaka Tokuda, Hiroyasu Makuuchi, Tomoo Tajima, Sonoko Habu.   

Abstract

There is increasing evidence that human hematopoietic stem cells can develop into lymphocytes expressing T cell surface markers in the organ culture of murine embryonic thymic lobes. If human T cells with functional maturity are inducible from human stem cells in the mouse, it may be a useful model to investigate human T cell development and the human immune response in vivo. To approach this, we produced a hybrid cluster of murine fetal thymic epithelial cells and human cord blood-derived CD34(+) cells (hu/m cluster) using reaggregate thymic organ culture, and subsequently implanted it under the kidney capsule of NOD/SCID mice. The implanted hu/m cluster grew in volume under the kidney capsule and contained increased numbers of CD4(+)CD8(+)cells as well as CD4 or CD8 single-positive cells with low CD1a expression. These lymphocytes were also shown to possess activity for producing IL-2 and IL-4. Characteristics similar to human T cells also developed in the thymus of newly established mice lacking NK activity from NOD/SCID mice. These results indicate that functionally mature T cells can develop in vivo from human hematopoietic progenitors in the murine environment composed of thymic epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12356677     DOI: 10.1093/intimm/dxf087

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  8 in total

1.  Induction and maintenance of IL-4 expression are regulated differently by the 3' enhancer in CD4 T cells.

Authors:  M Hanief Sofi; Yu Qiao; K Mark Ansel; Masato Kubo; Cheong-Hee Chang
Journal:  J Immunol       Date:  2011-01-31       Impact factor: 5.422

Review 2.  Challenges and strategies for generating therapeutic patient-specific hemangioblasts and hematopoietic stem cells from human pluripotent stem cells.

Authors:  Ann Peters; Paul W Burridge; Marina V Pryzhkova; Michal A Levine; Tea-Soon Park; Christopher Roxbury; Xuan Yuan; Bruno Péault; Elias T Zambidis
Journal:  Int J Dev Biol       Date:  2010       Impact factor: 2.203

Review 3.  Human intrathymic development: a selective approach.

Authors:  J Plum; M De Smedt; G Leclercq; T Taghon; T Kerre; B Vandekerckhove
Journal:  Semin Immunopathol       Date:  2008-10-17       Impact factor: 9.623

4.  Generation and Disease Model Relevance of a Manganese Enhanced Magnetic Resonance Imaging-Based NOD/scid-IL-2Rγc(null) Mouse Brain Atlas.

Authors:  Balasrinivasa R Sajja; Aditya N Bade; Biyun Zhou; Mariano G Uberti; Santhi Gorantla; Howard E Gendelman; Michael D Boska; Yutong Liu
Journal:  J Neuroimmune Pharmacol       Date:  2015-11-10       Impact factor: 4.147

5.  Regulation of in vitro human T cell development through interleukin-7 deprivation and anti-CD3 stimulation.

Authors:  Ekta S Patel; Starlyn Okada; Kevin Hachey; Li-jun Yang; Scott K Durum; Jan S Moreb; Lung-Ji Chang
Journal:  BMC Immunol       Date:  2012-08-16       Impact factor: 3.615

6.  Influence of age, irradiation and humanization on NSG mouse phenotypes.

Authors:  Jaclyn S Knibbe-Hollinger; Natasha R Fields; Tammy R Chaudoin; Adrian A Epstein; Edward Makarov; Sidra P Akhter; Santhi Gorantla; Stephen J Bonasera; Howard E Gendelman; Larisa Y Poluektova
Journal:  Biol Open       Date:  2015-09-09       Impact factor: 2.422

Review 7.  Genetically modified mouse models to help fight COVID-19.

Authors:  Channabasavaiah B Gurumurthy; Rolen M Quadros; Guy P Richardson; Larisa Y Poluektova; Suzanne L Mansour; Masato Ohtsuka
Journal:  Nat Protoc       Date:  2020-10-26       Impact factor: 13.491

8.  Thymic selection pathway regulates the effector function of CD4 T cells.

Authors:  Wei Li; M Hanief Sofi; Norman Yeh; Sarita Sehra; Brian P McCarthy; Dipak R Patel; Randy R Brutkiewicz; Mark H Kaplan; Cheong-Hee Chang
Journal:  J Exp Med       Date:  2007-08-27       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.